Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
... indicate that KRAS plays an important role in cell
growth regulation. In mCRC, EGFR transmits ... the nucleus, these signals instruct the cancer cell
to reproduce and metastasize, leading to cancer ... sometimes, even adequately modeled by computer or cell
culture systems or animal models. The length of ...
Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
... The initial focus will be on pancreatic beta cell
regeneration and survival, to restore beta cell
function in diabetes. The program builds on ... at GNF that has resulted in the discovery of beta cell
regeneration drug targets and candidates, and ...
Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
MDS is a heterogeneous group of blood stem cell
disorders of increasing incidence. MDS is characterized by ineffective blood cell
production involving one or more of the red cell, white cell
or platelet lineages and with MDS patients having ...
OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- cell
Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) ... that in patients with advanced non-small cell
lung cancer (NSCLC), the combination of OPAXIO ... compared to standard therapies.
Headquartered in Seattle, ...
Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
... from their peripheral blood and mixed with a cell
culture of the patient's own melanoma cells that ... months, p=.016). Eight patients in the dendritic cell
vaccine study experienced remarkable long-term, ... patient-specific biological treatments in its cell
biology laboratory, and provides a wealth of ...
Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.
... the largest and most established leaders in stem cell
innovation today announced a research and ... global regenerative technology leader and stem cell
research company. The partnership will allow ... a global leader in regenerative medicine and stem cell
R&D, to explore the utilization and potential ...
Injection Reverses Heart-Attack Damage
... heart defects. In the July 24 issue of cell
, they show that a growth factor called ... cells (cardiomyocytes) normally withdraw from the cell
cycle - meaning they stop dividing and ... at Children's, were able to restart the cell
cycle with NRG1, stimulating cardiomyocytes to ...
National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness
SEATTLE, July 21 /PRNewswire-FirstCall/ -- cell
Therapeutics (CTI) (Nasdaq and MTA: CTIC) ... the NCI research indicates that the tumor cell
DNA damaging effects of brostallicin are enhanced ... was active in a trabectedin-resistant cell
"These preclinical data provide ...
Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
... that a study of the gene regulation in multiple cell
lines by several of their estrogen receptor beta ... hormone therapy. The study also demonstrates the cell
type selectivity of Menerba (MF101) and ... of Bionovo's ERb selective drugs, in different cell
types. These compelling findings will serve as a ...
Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
... reovirus and chemotherapy against human non-small cell
lung cancer (NSCLC). The paper, entitled ... Reovirus and Chemotherapeutic Agents in Non-Small cell
Lung Cancer Cells" appears online in the July 14, ... significant multiple drug resistance in certain cell
lines," said Dr. Brad Thompson, President and CEO ...
Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
... due to the impermeability
of B. cepacia's cell
envelope. In addition, B. cepacia - just like ... rescue mechanisms that pump
tobramycin out of the cell
are inhibited by the fusion process. The ... maximum release of tobramycin into the bacterial cell
with inhibition of the clearance ...
Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
... which are pathways associated with programmed cell
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
... is a patented formulation of Mycobacterial cell
Wall-DNA Complex (MCC) developed by Bioniche for ... is a formulation of MCC, a sterile mycobacterial cell
wall-DNA complex composition that has a dual mode ... to the development of Bioniche's mycobacterial cell
wall technologies by means of a C$9.6 million ...
CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
... (treatment naive) patients with Squamous cell
Carcinoma of the Head and Neck. Early ... primary Head and Neck cancer (Oral Squamous cell
Carcinoma) during the impending Multikine Pivotal ... to utilize to launch aseptic filling for stem cell
produced therapies and other biological products. ...
Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
... clinical trials (MARVEL) to advance muscle stem cell
(myoblast) therapy for treating heart failure to ... of Medicine, discussed the difficulties of stem cell
therapy in scar tissue. "Cells of the myoblast ... therapy is at this time point the only stem cell
therapy that is making the claim to actually ...
Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
... member of the Roche Group, for the generation of cell
lines with novel characteristics for ... genes in a Chinese hamster ovary (CHO) cell
line. The milestone achievement triggered a ... protein production to streamline the process of cell
line production, increase the yield and improve ...
Alfacell Provides Shareholder Update
... genes, we added Onconase to three mesothelioma cell
lines at a dose which is achievable in humans, ... in all of these genes in the mesothelioma cell
lines were seen after treatment with Onconase ... to chemotherapy. Moreover, these data in cell
lines are complemented by most recent animal ...
Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
... neuron replacement program at California Stem cell
and UCI. These three programs represent an ... Neuron Replacement Program:
California Stem cell
(CSC) is preparing for a final FDA pre-IND ... for the use of these cells in development of a cell
replacement therapy for SMA Type I.
HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
... of the trial protocol. "This is the largest cell
therapy dose ranging trial ever undertaken in the ... promising results over a four-fold range of cell
concentrations administered weekly.
This ... both keratinocytes and fibroblasts, the two major cell
types found in human skin. Using a unique ...
UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
... Cancer Institute (UPCI) and the Gamida cell
Teva Joint Venture announced today that the ... clinical director of UPCI's Hematopoietic
Transplant Program. "Using umbilical cord blood ... 10th in funding from the NCI.
About Gamida cell
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
... reported through week 104 included basal cell
skin cancer (one patient), colon cancer (one patient) and small cell
lung cancer (one patient) in patients receiving SIMPONI 50 mg, and basal cell
skin cancer (three patients), prostate cancer ...
ThermoGenesis Announces National Institute of Health Grant
... FIRST-EVER NIH GRANT WILL BE USED TO DEVELOP cell
DELIVERY TECHNOLOGIES FOR REGENERATIVE MEDICINE ... The study will be conducted at the Company's stem cell
research laboratory and through a collaboration ... Officer of ThermoGenesis. "We will be using stem cell
concentrates prepared by our AXP(TM) AutoXpress ...
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
... orBec(R) conducted at 16 leading bone marrow/stem cell
transplantation centers in the US and France. ... cancer patients after receiving hematopoietic cell
transplantation. Unlike organ transplants where ... life-threatening complication of hematopoietic cell
transplantation. DOR expects to begin a ...
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
... of autoimmune type 1 diabetes, will preserve beta cell
function as measured by c-peptide, a surrogate measure of beta cell
function. The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell
function. For information about DEFEND, please ...
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
... the immune system, such as DLBCL, mantle cell
lymphoma and follicular lymphoma(2). Up to 60% of ... Hodgkin's disease, follicular lymphoma, mantle cell
lymphoma, DLBCL and small lymphocytic lymphoma; ... (53% ORR), follicular lymphoma (50% ORR), mantle cell
lymphoma (32% ORR), DLBCL (30% ORR) and small ...
Three Surgeons in East Texas Are Successfully Integrating a Novel Stem Cell Procedure for Spine Surgeries
... Stem cell
Technologies for Surgery
TEXARKANA, Texas, ... /PRNewswire/ -- A new breakthrough in adult stem cell
technology has three Texarkana neurosurgeons ... adoption to benefit all patients in need of cell
"As a neurosurgeon, I pride myself ...
Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
ORLANDO, Fla., June 3 /PRNewswire-FirstCall/ -- cell
Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) ... to 2.0, OPAXIO increases tumor specific radiation cell
kill by a factor of 7.2 to 8.4 -fold (Milas Luka ... locally advanced adenocarcinoma or squamous cell
carcinoma of the esophagus or gastro-esophageal ...
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
... Myeloma Program, Bone Marrow and Blood Stem cell
Transplantation at St. Vincent's Comprehensive ... and dexamethasone during the "Lymphoma and Plasma cell
Disorders" poster session.
"In spite of ... prior treatment with all approved agents and stem cell
Sustained Clinical Benefit in ...
Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
... which are pathways associated with programmed cell
Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
... were hematologic, including anemia (low red blood cell
count), neutropenia (low white blood cell
count) and thrombocytopenia (low blood platelet ... (Stage IV or cancer that has spread) non-small cell
lung cancer for whom surgery is not possible.
Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
... which are pathways associated with programmed cell
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
... according to disease type, including non-small cell
lung cancer, small cell
lung cancer, ovarian cancer and renal cancer. ... responses observed in renal cancer and small cell
lung cancer patients. A total of 55 patients ...
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
... the Phase III ZODIAC study in advanced non-small cell
lung cancer patients, with the investigational ... rash, diarrhea and neutropenia (low white blood cell
count) (ZODIAC). Incidence of protocol-defined ... prostate cancer combined(4).
lung cancer accounts for around 85% of all lung ...
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
... is designed to inhibit both angiogenesis and cell
proliferation by targeting and binding to ... transduction and are important in controlling cell
growth/angiogenesis, differentiation, ... AKT and mTOR is also known to promote tumor cell
survival, proliferation, and growth. ...
Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
... data from the Phase II, open-label study in renal cell
carcinoma (RCC) demonstrated a 27 percent partial ... untreated patients with predominantly clear cell
RCC. BAY 73-4506 (160 mg) was administered once ... studies to prevent the proliferation of tumor cell
lines while promoting apoptosis (cell death) by ...
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
... for cancer, as a treatment for advanced renal cell
carcinoma. Abstract #5034, entitled, "Phase II study of perifosine in metastatic renal cell
carcinoma (RCC) progressing after prior therapy ... to patients with 2nd or 3rd line metastatic renal cell
cancer. We are grateful to Dr. Vogelzang, Dr. ...
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
... TKI258 (dovitinib lactate) in metastatic renal cell
carcinoma (mRCC) patients refractory to approved ... study of heavily pre-treated metastatic renal cell
carcinoma patients demonstrated that TKI258 500 ... of HSP90, a key target that regulates tumor cell
survival and division, through the use of AUY922, ...
Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
... Small Molecule Stem cell
Modulator Administered in Dual Cord Blood ... clinical trial of FT1050, a small molecule Stem cell
Modulator (SCM) designed to increase hematopoietic stem cell
(HSC) number and function through its activation ...
Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
... fixatives are developed to both preserve cell
morphology and fix the state of cellular ... analysis. LCM is used to isolate specific cell
populations from many different types of cells ... subsequent molecular assays is specific to that cell
population. RPMA enables sensitive, quantitative, ...
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
... (T) in patients with relapsed or refractory small cell
lung cancer (SCLC) after prior platinum ... #8582; Poster Board #S11; Lymphoma and Plasma cell
Disorders, May 30, 8:00 a.m.-12:00 p.m.
... advanced solid tumors and extensive-stage small cell
lung cancer (ES-SCLC). Abstract #e13502; ...